CN103917876B - 用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 - Google Patents

用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 Download PDF

Info

Publication number
CN103917876B
CN103917876B CN201280054323.8A CN201280054323A CN103917876B CN 103917876 B CN103917876 B CN 103917876B CN 201280054323 A CN201280054323 A CN 201280054323A CN 103917876 B CN103917876 B CN 103917876B
Authority
CN
China
Prior art keywords
lipid
cer
control
sample
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280054323.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103917876A (zh
Inventor
R·拉克松恩
K·埃克罗斯
R·霍尔姆
M·詹尼斯
R·卡塔恩
K·塔拉索夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zora Biosciences Oy
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of CN103917876A publication Critical patent/CN103917876A/zh
Application granted granted Critical
Publication of CN103917876B publication Critical patent/CN103917876B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN201280054323.8A 2011-11-08 2012-11-07 用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 Active CN103917876B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556909P 2011-11-08 2011-11-08
US61/556,909 2011-11-08
EP11188328.6A EP2592423A1 (en) 2011-11-08 2011-11-08 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP11188328.6 2011-11-08
PCT/EP2012/071972 WO2013068373A2 (en) 2011-11-08 2012-11-07 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Publications (2)

Publication Number Publication Date
CN103917876A CN103917876A (zh) 2014-07-09
CN103917876B true CN103917876B (zh) 2018-02-02

Family

ID=45033777

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280054323.8A Active CN103917876B (zh) 2011-11-08 2012-11-07 用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志

Country Status (7)

Country Link
US (3) US9052328B2 (cg-RX-API-DMAC7.html)
EP (3) EP2592423A1 (cg-RX-API-DMAC7.html)
JP (1) JP6388283B2 (cg-RX-API-DMAC7.html)
CN (1) CN103917876B (cg-RX-API-DMAC7.html)
CA (1) CA2853220A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202157A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013068373A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
ES2552371T3 (es) * 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)
CN105723223B (zh) * 2013-11-14 2019-04-09 雀巢产品技术援助有限公司 预测健康衰老的脂质生物标志物
NZ724790A (en) 2014-04-10 2022-07-29 MEP Equine Solutions LLC Method for the quantification of parasite eggs in feces
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
EP3177939A1 (en) 2014-09-11 2017-06-14 Liposcience, Inc. Cardiovascular risk evaluations using a risk parameter that includes an hdl and inflammatory biomarker interaction parameter
WO2016100549A2 (en) 2014-12-16 2016-06-23 Washington University Ceramides for evaluating risk of cardiovascular disease
US20180238914A1 (en) * 2015-08-19 2018-08-23 Metanomics Gmbh Means and methods for diagnosing cardiac disease in a subject
ES2861401T3 (es) * 2015-10-20 2021-10-06 Medimmune Llc Marcador de diagnóstico para arteriopatía coronaria
WO2017097852A2 (en) 2015-12-07 2017-06-15 Zora Biosciences Oy Use of ceramides and lpls in diagnosing cvd
CN105424841B (zh) * 2015-12-25 2017-11-03 齐炼文 用于诊断冠状动脉粥样硬化的代谢标志物
CN107014942A (zh) * 2017-05-05 2017-08-04 北京骐骥生物技术有限公司 利用脂质生物标志物预测糖尿病冠心病的方法
CN107144624B (zh) * 2017-05-15 2021-01-05 中国科学院生态环境研究中心 甄别二氧化硅颗粒来源的方法
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
EP3891509A1 (en) 2018-12-06 2021-10-13 Zora Biosciences OY Biomarkers for cardiovascular events
CN113533754A (zh) * 2021-07-12 2021-10-22 北京市心肺血管疾病研究所 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用
WO2024192471A1 (en) * 2023-03-20 2024-09-26 Baker Heart and Diabetes Institute Methods of assessing metabolic health

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316863A (zh) * 2005-09-02 2008-12-03 生物发明国际公司 用于诱导动脉粥样硬化斑块消退的免疫治疗
US20090197242A1 (en) * 2006-04-24 2009-08-06 Kaddurah-Daouk Rima F Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease
CN101772701A (zh) * 2007-06-08 2010-07-07 奎斯特诊断投资公司 通过差分带电荷微粒迁移率进行脂蛋白分析
WO2011063048A2 (en) * 2009-11-17 2011-05-26 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
WO2011063470A1 (en) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489633T1 (de) * 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
WO2004038381A2 (en) 2002-10-25 2004-05-06 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
DE102006034153B4 (de) 2006-07-24 2018-02-08 Magna powertrain gmbh & co kg Getriebe
EP2153236A1 (en) 2007-06-07 2010-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for assessing the risk of a cardiovascular disease and for diagnosing dyslipidemia
EP2048243A1 (en) 2007-09-24 2009-04-15 sanofi-aventis Use of clec1B for the determination of cardiovascular and thrombotic risk
US9213030B2 (en) 2008-01-28 2015-12-15 National University Of Singapore Lipid tumour profile
AU2009224114B2 (en) 2008-03-12 2013-02-21 Otago Innovation Limited Biomarkers
ES2640900T3 (es) 2008-10-30 2017-11-07 Firalis Biomarcadores
US20110034419A1 (en) * 2009-06-27 2011-02-10 Musc Foundation For Research Development Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease
NO2385374T3 (cg-RX-API-DMAC7.html) 2010-05-05 2014-06-07
EP2583107A2 (en) 2010-06-20 2013-04-24 Zora Biosciences OY Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US9664698B2 (en) 2011-04-08 2017-05-30 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316863A (zh) * 2005-09-02 2008-12-03 生物发明国际公司 用于诱导动脉粥样硬化斑块消退的免疫治疗
US20090197242A1 (en) * 2006-04-24 2009-08-06 Kaddurah-Daouk Rima F Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease
CN101772701A (zh) * 2007-06-08 2010-07-07 奎斯特诊断投资公司 通过差分带电荷微粒迁移率进行脂蛋白分析
WO2011063048A2 (en) * 2009-11-17 2011-05-26 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
WO2011063470A1 (en) * 2009-11-27 2011-06-03 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages:investigating differential effects among statins;Bergheanu Sandrin C et al;《Current medical reseach and opinion》;20080901;第24卷(第9期);2477-2487 *
Predicting CHD risk in patients with diabetes mellitus;W.W.TEO et al;《Diabetic medicine》;20010501;第18卷(第5期);341-344 *

Also Published As

Publication number Publication date
CA2853220A1 (en) 2013-05-16
EP2592423A1 (en) 2013-05-15
US9423406B2 (en) 2016-08-23
JP2014532885A (ja) 2014-12-08
WO2013068373A3 (en) 2013-07-18
US20160320418A1 (en) 2016-11-03
US9052328B2 (en) 2015-06-09
HK1202157A1 (en) 2015-09-18
JP6388283B2 (ja) 2018-09-12
US20150260737A1 (en) 2015-09-17
EP2776841B1 (en) 2017-01-11
EP3208617A3 (en) 2017-11-01
CN103917876A (zh) 2014-07-09
EP2776841A2 (en) 2014-09-17
EP3208617A2 (en) 2017-08-23
WO2013068373A2 (en) 2013-05-16
US9863965B2 (en) 2018-01-09
EP3208617B1 (en) 2021-02-24
US20140295467A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CN103917876B (zh) 用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志
CN104024860B (zh) 用于预测接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志
US12270816B2 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
CN102971633B (zh) 针对动脉粥样硬化和心脏血管疾病的脂质组学生物标志

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant